BioCentury
ARTICLE | Company News

Isis Pharmaceuticals, Pfizer deal

November 12, 2012 8:00 AM UTC

Isis will receive a $1.3 million milestone payment from Pfizer triggered by the pharma's decision to advance EXC 001 ( PF-06473871) into Phase II testing. Pfizer gained rights to EXC 001 through its ...